Skip to main content

Table 3 Univariate and multivariate regression analysis to identify predictors for hepatotoxicity related to erlotinib administration in lung cancer patients

From: Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study

Characteristics Unadjusted OR
(95% CI)
Model I Model II
Adjusted OR (95% CI) Attributable risk Adjusted OR (95% CI) Attributable risk
Male 0.598 (0.212–1.688) 0.251 (0.060–1.048)   0.266 (0.065–1.084)  
Age ≥ 65 2.623 (0.902–7.633) 3.198 (1.023–9.997)* 68.7 3.540 (1.123–11.164)* 71.8
BSA ≥ 1.6 1.398 (0.460–4.244) 3.545 (0.787–15.972)   3.188 (0.723–14.053)  
PPI 3.528 (0.984–12.651) 3.529 (0.916–13.595)    
H2 blocker or PPI 3.083 (1.056–9.000)*    3.454 (1.114–10.713)* 71.0
  1. For model I construction, sex, age, BSA and PPI were included for analysis. For model II construction, sex, age, BSA and H2 blocker or PPI were included for analysis
  2. BSA body surface area, PPI proton pump inhibitor
  3. *P < 0.05